US biotechnology firm Gilead Sciences has received European Commission (EC) approval to market its once-daily Tybost (cobicistat 150mg tablets), a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines.
The marketing authorisation will see Tybost commercialised in all 28 countries of the EU.
Go deeper with GlobalData
Tybost was developed as a boosting agent for the HIV protease inhibitors atazanavir 300mg once daily and darunavir 800mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection.
The EU approval follows promising results from a Phase III study which showed Tybost to be non-inferior to ritonavir when administered with an antiretroviral regimen of atazanavir plus Truvada (emtricitabine 200mg and tenofovir disoproxil (as fumarate) 245mg) in HIV-infected treatment-naïve adults.
The pharmacokinetic data also demonstrated that Tybost increases blood levels of atazanavir and darunavir similar to ritonavir.
The company said Tybost should only be co-administered with atazanavir or darunavir.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGilead Sciences executive vice president of research and development Norbert Bischofberger said: "Gilead is pleased to offer HIV patients who rely on protease inhibitors a new boosting option to help facilitate once-daily dosing – an important factor in supporting treatment adherence."
Tybost, a cytochrome P450 3A (CYP3A) inhibitor, acts only as a pharmacokinetic enhancer and has no antiviral activity.
It is a component of Gilead’s Stribild (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir disoproxil (as fumarate) 245mg), a once-daily complete single tablet regimen for the treatment of HIV-1 infection that was approved in the US in August 2012 and in the European Union in May 2013.
Gilead submitted a new drug application to the US Food and Drug Administration (FDA) for Tybost as a single agent in June 2012 but received a FDA complete response letter in April 2013.
However, it received Canadian approval and is now working on resubmitting the application to the FDA.
Image: Tybost was developed as a boosting agent for the HIV protease inhibitors. Photo: Courtesy of FreeDigitalPhotos.net.
